Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869713 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
A Phase 2 study of Rift Valley Fever, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT00869713 is a Phase 2 study of Rift Valley Fever that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 98 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00869713, a Phase 2 study of Rift Valley Fever, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
Conditions Studied
Interventions
- BIOLOGICAL Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Study Locations (1)
Maryland
- U.S. Army Medical Research Institute of Infectious Diseases - Fort Deterick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-09 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869713
The ClinicalTrials.gov registry entry for NCT00869713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rift Valley Fever appearing as the primary indexed condition, and to 1 intervention - of which Inactivated, Dried (TSI-GSD 200), RVF Vaccine is the first listed.
NCT00869713 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00869713 about?
NCT00869713 is a clinical study titled "Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated". This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
What is the current status of trial NCT00869713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2009-09. Estimated completion is 2021-05.
What conditions does trial NCT00869713 study?
This clinical trial studies the following conditions: Rift Valley Fever.
What interventions are being tested in trial NCT00869713?
The interventions under investigation include: Inactivated, Dried (TSI-GSD 200), RVF Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00869713?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00869713 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rift Valley Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.